Table 5.
Summary of drug combinations in U-CH2 cells.
| Effect level | Drug 1 | Drug 2 | Ratio | CI | UCL | LCL |
|---|---|---|---|---|---|---|
| 50% | Afatinib | Palbociclib | 0.096:1 | 0.68 | 1.45 | 0.33 |
| 0.38:1 | 0.52 | 1.76 | 0.25 | |||
| 1.5:1 | 0.59 | 5.47 | 0.40 | |||
| 50% | Afatinib | RDEA119 | 0.074:1 | 1.04 | 2.25 | 0.49 |
| 0.29:1 | 0.98 | 2.78 | 0.48 | |||
| 1.2:1 | 0.53 | > 10 | 0.36 | |||
| 75% | Afatinib | AZD2014 | 0.62:1 | 0.71 | 2.37 | 0.22 |
| 2.5:1 | 0.83 | 1.41 | 0.49 | |||
| 10:1 | 0.75 | 1.14 | 0.50 | |||
| 75% | Palbociclib | RDEA119 | 0.19:1 | 1.00 | > 10 | 0.33 |
| 0.76:1 | 0.57 | 5.60 | 0.06 | |||
| 3.1:1 | 0.38 | > 10 | 0.03 | |||
| 75% | RDEA119 | AZD2014 | 2.1:1 | 1.77 | > 10 | 0.08 |
| 8.5:1 | 3.02 | > 10 | 1.16 | |||
| 34:1 | 1.63 | 4.97 | 0.54 |
Each CI was calculated at the specified effect level, along with upper and lower confidence limits (UCL and LCL). No combinations had significant synergy.